ENTECAVIR MALEATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H15N5O3.C4H4O4
Molecular Weight	393.352
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C=C1[C@]([H])(CO)[C@]([H])(C[C@]1([H])n2cnc3c2[nH]c(=N)nc3O)O.C(\[H])(=C(\[H])/C(=O)O)/C(=O)O

InChI

InChIKey=UEXBBJAYBDAHLG-FJESMAGSSA-N

InChI=1S/C12H15N5O3.C4H4O4/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;5-3(6)1-2-4(7)8/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1-2H,(H,5,6)(H,7,8)/b;2-1-/t6-,7-,8-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C4H4O4
Molecular Weight	116.0723
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	C12H15N5O3
Molecular Weight	277.2797
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_prntlbl.PDF
Curator's Comment:: Description was created based on several resourses, including http://www.drugs.com/monograph/entecavir.html and http://www.drugbank.ca/drugs/DB00442

BARACLUDE® is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It inhibits all three steps in the viral replication process. By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity. Entecavir is used for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 232 Target ID: CHEMBL2311221 Sources: http://www.drugbank.ca/drugs/DB00442	Inhibitor 7728		0.004 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hepatitis B 52 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_prntlbl.PDF	Primary		Approved 8043	Entecavir Approved Use BARACLUDE (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Launch Date 1.11205443E12

C_max

Value	Dose	Analyte	Population
4.23 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ENTECAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.2 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
14.78 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
26.38 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ENTECAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
129.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
148.89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17050790/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
138.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
87% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	0.5 mg 1 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ENTECAVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 mg 1 times / day steady, oral Highest studied dose Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf Page: 6.1	unhealthy, adult n = 183 Health Status: unhealthy Condition: hepatitis B Age Group: adult Sex: unknown Population Size: 183 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf Page: 6.1	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf Page: 6.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467	inhibitor 1604 inducer 355	inhibitor 1702	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 98 CYP1A2 1383 CYP2C19 1325 CYP2B6 717 CYP2E1 790 P-gp 1330	CYP 236 UGT enzymes 18 P-gp 1400 MRP4 73 BCRP 515 OCT3 75 OCTN2 44	CYP 70 CYP1A2 637 CYP2C19 269 CYP3A4/5 108 CYP2B6 501

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1514	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42.0	inconclusive
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with phenacetin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP2B6 884	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with S-mephentytoin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with S-mephentytoin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP2C9 1648	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with diclofenac Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with bufuralol Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP2E1 871	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with p-nitrophenol Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP3A4 1772	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155	no [IC50 >300 uM]	no (co-administration study) Comment: at clinically relevant concentrations entecavir inhibitied catalytic activities no greater than 9% with testosterone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 42, 154, 155
CYP 132	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 4, 16	no
CYP 132	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 4, 16	no
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 17.0	no
CYP2B6 884	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 17.0	no
CYP2C19 1392	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 17.0	no
CYP2C9 1648	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 17.0	no
CYP3A4/5 293	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 17.0	no

Drug as victim

Target	Modality	Activity
UGT enzymes 18	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 46.0	likely
CYP 236	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 4, 16	no
P-gp 1400	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_biopharmr.PDF Page: 5.0	no
BCRP 515	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/28627473/	yes
MRP4 73	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/28627473/	yes
OCT3 75	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/28062543/	yes
OCTN2 44	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/28062543/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_pharmr.PDF Page: 12, 13, 14

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA001HWV	http://www.aablocks.com/goods/Goods/detail?id=AA001HWV
AEchem Scientific Corp., USA	AE030999	http://www.aechemsc.com/info_products/AE030999.php
AHH Chemical co.,ltd	API-1857	http://www.ahhchemical.com/product/API-1857.html
AHH Chemical co.,ltd	API-1867	http://www.ahhchemical.com/product/API-1867.html
AK Scientific, Inc. (AKSCI)	71985	http://www.aksci.com/item_detail.php?cat=71985
AK Scientific, Inc. (AKSCI)	J90027	http://www.aksci.com/item_detail.php?cat=J90027
Achemtek	0104-042584	http://www.achemtek.com/142217-69-4
Acorn PharmaTech	ACN-040790	http://www.acornpharmatech.com/
Active Biopharma	ABP001043	http://www.activebiopharma.com/142217-69-4
Alfa Chemistry	AP142217694	https://reagents.alfa-chemistry.com/product/entecavir-cas-142217-69-4-4798.html
Ambinter	Amb22167451	http://www.ambinter.com/reference/22167451
Aromalake	LS41110	http://www.aromalake.com/Entecavir-p4151.html
AstaTech, Inc.	27355	http://www.astatechinc.com/CPSResult.php?CRNO=30226
Aurora Fine Chemicals LLC	A17.935.672	http://online.aurorafinechemicals.com/info?ID=A17.935.672
Aurora Fine Chemicals LLC	K16.552.237	http://online.aurorafinechemicals.com/info?ID=K16.552.237
Aurum Pharmatech LLC	S-7388	http://www.Aurumpharmatech.com/Product/ProductDetails/S_7388
AvaChem Scientific	2193	http://www.avachem.com/productSearch.asp?2193
Axon MedChem	3239	https://www.axonmedchem.com/product/3239
BLD Pharm	BD127327	http://www.bldpharm.com/products/142217-69-4.html
Boerchem	BC677668	http://www.boerchem.com/?product_39560.html
CSNpharm	CSN10911	https://www.csnpharm.com/products/entecavir.html
Chem Scene	CS-3160	http://www.chemscene.com/142217-69-4.html
ChemMol	2100032	http://www.chemmol.com/chemmol/2100032.html
ChemMol	30108505	http://www.chemmol.com/chemmol/30108505.html
ChemMol	44009982	http://www.chemmol.com/chemmol/44009982.html
ChemMol	49401413	http://www.chemmol.com/chemmol/49401413.html
ChemMol	81412018	http://www.chemmol.com/chemmol/81412018.html
Chemenu	CM131589	http://www.chemenu.com/products/CM131589
Chemspace	CSSB00016989056	https://chem-space.com/CSSB00016989056
Clearsynth	CS-T-21655	http://www.clearsynth.com/en/CST21655.html
Glentham Life Sciences	GP8732	http://www.glentham.com/products/product/GP8732/
Lab Network	LN00188804	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188804
Matrix Scientific	90228	https://www.matrixscientific.com/090228.html
MedChem Express	HY-13623	https://www.medchemexpress.com/Entecavir.html
MuseChem	R056572	https://www.musechem.com/product/R056572.html
OChem	9946	http://www.ocheminc.com/index.php?act=psearch&pid=217E694
Oakwood	93332	http://www.oakwoodchemical.com/p-87765-093332.aspx
Parchem	18217	http://www.parchem.com/chemical-supplier-distributor/Entecavir-008217.aspx
Renno Tech	RL01752	http://www.rennotech.com/product_show.asp?id=2001
Sigma-Aldrich	SML1103_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/sml1103?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S527206	http://www.smolecule.com/products/s527206
Specs	AR-270/43507901	http://www.specs.net/enter.php?specsid=AR-270/43507901
Synblock Inc	PB30663	http://www.synblock.com/product/209216-23-9.html
Synchem UG and Co KG	70537	http://www.synchem.de/chemical_Entecavir.html
TCI (Tokyo Chemical Industry)	E0899	http://www.tcichemicals.com/eshop/en/us/commodity/E0899/index.html
THE BioTek	bt-267352	https://www.thebiotek.com/product/inhibitors/bt-267352
THE BioTek	bt-505445	https://www.thebiotek.com/product/others/bt-505445
Tocris	6234	https://www.tocris.com/products/entecavir_6234
VladaChem	VL282225-25mg	https://www.vladachem.com/product.php?products=142217-69-4
Yuhao Chemical	RT5843	http://www.chemyuhao.com/142217-69-4.html
abcr GmbH	AB436292	http://www.abcr.com/shop/en/AB436292
abcr GmbH	AB449610	http://www.abcr.de/shop/en/AB449610
eNovation Chemicals	D371231	http://www.enovationchem.com/productDetails.asp?productID=D371231
eNovation Chemicals	D523180	https://www.enovationchem.com/ProductDetails.asp?ProductID=D523180
eNovation Chemicals	Y0974221	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974221
iChemical	EBD42532	http://www.ichemical.com/products/142217-69-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
[Entecavir therapy against hepatitis B].	2004 Aug	15453342
[Treatment and selection criteria for chronic hepatitis B].	2004 Aug	15453336
[Recent advances in the treatment of fulminant hepatitis B].	2004 Aug	15453330
[Advances in the treatment of acute hepatitis B].	2004 Aug	15453324
Management of hepatitis B patients with antiviral resistance.	2004 Dec	15651760
Entecavir for the treatment of chronic hepatitis B.	2004 Dec	15566330
Gateways to clinical trials.	2004 Nov	15632957
Emerging treatments in chronic hepatitis B.	2004 Nov	15571480
[Treatment of hepatitis B].	2004 Nov 7	15573894
Gateways to clinical trials.	2004 Sep	15538546
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.	2005	16152756
Management of HBV/HIV-coinfected Patients.	2005	16103981
Clinical trial results of new therapies for HBV: implications for treatment guidelines.	2005	16103979
Current treatment of chronic hepatitis B: benefits and limitations.	2005	16103978
Drugs in development for hepatitis B.	2005	16033287
US approves new HBV drug.	2005 Apr	16110549
Managing hepatitis B coinfection in HIV-infected patients.	2005 Aug	16091258
The current status of antiviral therapy of chronic hepatitis B.	2005 Dec	16461210
Hepatitis B virus infection: current status.	2005 Dec	16378788
Complications in treating chronic hepatitis B in patients with HIV.	2005 Dec	16318434
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.	2005 Dec	16168522
Gateways to clinical trials.	2005 Jan-Feb	15834459
FDA notifications. Entecavir is approved for chronic hepatitis B infection in adults.	2005 Jul	16114113
Chronic hepatitis B--treatment with nucleoside analogues.	2005 Jul	16108169
Entecavir.	2005 Jul	16075486
[A study of the dosage and efficacy of entecavir for treating hepatitis B virus].	2005 Jul	16042878
Treatment of chronic hepatitis B.	2005 Jul	15985003
New treatment for chronic hepatitis B.	2005 Jul-Aug	16255066
Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment.	2005 Jun	16007397
Management of patients co-infected with hepatitis B virus and HIV.	2005 Jun	15919623
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.	2005 Jun	15915463
Entecavir (Baraclude) for chronic hepatitis B.	2005 Jun 6	15933618
Current and future treatment of chronic hepatitis B.	2005 Mar	15756148
[Treatment of chronic hepatitis B].	2005 Mar 31	15913114
Gateways to clinical trials.	2005 May	16082427
New drugs and dosage forms.	2005 May 1	15892212
New drugs: entecavir, ibandronate sodium, and pegaptanib sodium.	2005 May-Jun	15991765
Gateways to clinical trials.	2005 Nov	16357953
A review of entecavir in the treatment of chronic hepatitis B infection.	2005 Nov	16307706
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.	2005 Oct	16230074
Clevudine for the treatment of chronic hepatitis B virus infection.	2005 Oct	16185170
Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.	2005 Sep 13	16159399
[New aspect in the treatment of chronic hepatis B].	2005 Sep 7	16212002
Optimizing management strategies in special patient populations.	2006	16448449
Looking to the future: new agents for chronic hepatitis B.	2006	16448448
Therapeutic options for chronic hepatitis B: considerations and controversies.	2006	16448447
Introduction to chronic hepatitis B infection.	2006	16448446
Emerging therapeutics for chronic hepatitis B.	2006	16409142
Treatment algorithm for chronic hepatitis B in HIV-infected patients.	2006	16352368
Cellular and virological mechanisms of HBV drug resistance.	2006 Feb	16364492

Patents

Sample Use Guides

In Vivo Use Guide

Nucleoside-naive Individuals Oral 0.5 mg once daily. Lamivudine-refractory HBV or known lamivudine- or telbivudine-associated resistance mutations Oral 1 mg once daily

Route of Administration: Oral

In Vitro Use Guide

Dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients were treated with 0.05 ug/mL of Entecavir.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 02:33:48 UTC 2021` Edited by `admin` on `Sat Jun 26 02:33:48 UTC 2021`
Record UNII	92A92XBK4S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENTECAVIR MALEATE

Common Name

English

6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL)-, (2Z)-2-BUTENEDIOATE (1:1)

Systematic Name

English

ENTECAVIR MALEATE [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

92A92XBK4S

Created by admin on Sat Jun 26 02:33:48 UTC 2021 , Edited by admin on Sat Jun 26 02:33:48 UTC 2021

PRIMARY

CAS

911138-73-3

Created by admin on Sat Jun 26 02:33:48 UTC 2021 , Edited by admin on Sat Jun 26 02:33:48 UTC 2021

PRIMARY

PUBCHEM

135449303

Created by admin on Sat Jun 26 02:33:48 UTC 2021 , Edited by admin on Sat Jun 26 02:33:48 UTC 2021

PRIMARY

Related Record Type Details


					NNU2O4609D

ENTECAVIR ANHYDROUS

PARENT -> SALT/SOLVATE

Related Record Type Details


					NNU2O4609D

ENTECAVIR ANHYDROUS

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_prntlbl.PDFCurator's Comment:: Description was created based on several resourses, including http://www.drugs.com/monograph/entecavir.html and http://www.drugbank.ca/drugs/DB00442

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_BARACLUDE_prntlbl.PDF
Curator's Comment:: Description was created based on several resourses, including http://www.drugs.com/monograph/entecavir.html and http://www.drugbank.ca/drugs/DB00442

C_max

T_1/2

F_unbound

Drug as perpetrator